BristolMyers Squibb\'s Opdivo plus chemotherapy fails to prolong survival in NSCLC httpbit.ly2SGPeQb $BMY pharma

Bristol-Myers Squibb's Opdivo plus chemotherapy fails to prolong survival in NSCLC http://bit.ly/2SGPeQb  $BMY #pharma

19:00 EDT 24 Jul 2019 | FirstWord Pharma

Bristol-Myers Squibb's Opdivo plus chemotherapy fails to prolong survival in NSCLC http://bit.ly/2SGPeQb  $BMY #pharma

More From BioPortfolio on "Bristol-Myers Squibb's Opdivo plus chemotherapy fails to prolong survival in NSCLC http://bit.ly/2SGPeQb  $BMY #pharma"